Hawaii IDeA Center for Pediatric and Adolescent Clinical Trials3 (HIPACT3) - The principal objective of the Hawaii IDeA Center for Pediatric and Adolescent Clinical Trials (HIPACT) is to strengthen a pediatric clinical trials team in Hawaii to participate in community relevant, and scientifically valid multicenter clinical trials, as a partner in the IDeA States Pediatric Clinical Trials Network (ISPCTN). The overarching goal is to improve the health and wellbeing of the population of Hawaii. As the western most IDeAeligible state, Hawaii is home to a large Native Hawaiian, Pacific Islander and Asian population. The Hawaiian archipelago consists of 8 islands spreading over 1500 miles, creating communities at high risk for suboptimal medical care. In Hawaii, very few clinical trials have targeted children from Native Hawaiian, Pacific Islander and Asian population or children from rural areas. The only tertiary care pediatric medical center, Kapi’olani Medical Center for Women and Children will serve as the home for HIPACT3 with an innovative fusion of the local university medical school, John A. Burns School of Medicine Department of Pediatrics, and several crucially important community health centers in rural areas across the Hawaiian islands. The community health centers, including the largest community health center in the state of Hawaii, the Waianae Coast Comprehensive Health Center (WCCHC), largely serve Native Hawaiians and Other Pacific Islanders. Moreover, our network will be enhanced by the numerous local, regional and national faculty development opportunities aimed to improve the design, participation and dissemination of clinical trials. The following HIPACT3 Specific Aims are proposed: 1) Provide access to high quality multicenter clinical research to children and adolescents from Native Hawaiian, Pacific Islander and Asian populations; 2) Actively participate in and contribute to clinical trials in ISPTCN with a clinical trial proposal; 3) Strengthen research infrastructure and training for young investigators to enhance capacity for clinical trials; and 4) Engage communities to enhance the impact of clinical trials and distribute knowledge to implement clinical improvement for Hawaii. Thus, HIPACT3 is well positioned with a unique opportunity, experienced leadership, committed partners and community leaders to work with ISPCTN and successfully enroll infants, children and adolescents from Hawaii to contribute to ISPCTN approved trials.
